Lisa Delfini, Chief Financial Officer at Trevi Therapeutics, Inc. (TRVI), sold 8,474 shares at $2.45 ($21K) on 2023-02-13, disclosed to the SEC on 2023-02-15.
Scheduled sale ($21k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| TRVI | SELL | 2023-09-13 | $2K | — | Filing → |
| TRVI | SELL | 2023-08-14 | $2K | — | Filing → |
| TRVI | SELL | 2023-07-12 | $2K | — | Filing → |